GeneLink Subsidiary GeneWize Launches Revolutionary LifeMap Me™ DNA Customized Skin Serum
GeneWize Affiliates celebrate over $11M first year sales at Annual Leadership Conference
Orlando, Florida – August 12, 2009 – GeneLink, Inc. (OTCBB: GNLK.OB), (the "Company"), a leading consumer genomics biotech company, today reported that its wholly owned subsidiary, GeneWize Life Sciences, Inc. ("GeneWize"), launched its new LifeMap Me™ DNA customized skin serum and welcomed leaders and sales professionals (Affiliates) from across the nation to Orlando, Florida to celebrate first year sales of over $11M and enjoy three days of recognition, learning and festivity.
Sharon Tahaney, GeneWize Sr. V.P of Sales & Marketing stated: "New was a common theme during this event, and the biggest and brightest star among the 'new' products and concepts for GeneWize was the introduction of the LifeMap Me™ DNA customized skin repair serum. Our new serum has been branded "ME" to celebrate the fact that each serum is "Made Exclusively" to respond to specific skin aging predispositions made apparent by each individual's skin-health DNA assessment. LifeMap Me™ DNA Customized Skin Repair Serum will be available for sale through independent GeneWize Affiliates starting mid-September, 2009."
Other Highlights of the event included:
Launch of the customized GeneWize LifeMap Magazine, designed to help Affiliates share the GeneWize story. Starting in mid-September, the inclusion in of a DNA Collection Kit in each LifeMap Magazine, making the path between understanding the importance of DNA customized products and peeking into one's own DNA as close as the magazine in hand.
- Preview of the newly designed GeneWize Web site complete with a multitude of new marketing and contact tools including social networking support within the GeneWize community as well as social networking at large with FaceBook, Twitter and others.
- New Opportunity Hotline presentation number: 877-263-6949; New Opportunity Postcards and a New Opportunity Presentation.
- Personal appearances and presentations by members of GeneLink's Scientific Advisory Board.
Monte Taylor, GeneLink and GeneWize CEO commented: "The overwhelming response of our LifeMap Me™ customized skin serum launch at our First Annual Leadership Celebration was a resounding success and reconfirms the momentum building in GeneWize and our expectations for continued growth in the coming year. We are delighted that our GeneWize Affiliates have partnered with us in the direct-selling marketing channel to help create over $11M in sales from our brief pre launch period through the first year of GeneWize business." He added, "Affiliate feedback from the event in response to the new serum introduction, and all other marketing initiatives was tremendously positive. We are looking forward to a bright future."
About GeneLink, Inc:
GeneLink is a leading biosciences company specializing in consumer genomics. GeneLink's patented and patent pending technologies include proprietary genetic assessments linked to personalized health, beauty and wellness applications. Its DNA assessments provide information that enables the customization of nutritional products, skincare products and health maintenance regimens designed to fulfill individual consumer needs. For more information visit: www.genelinkbio.com
About GeneWize Life Sciences, Inc.:
GeneWize is the first Direct Selling industry company to focus exclusively on providing individually customized nutritional and skin care formulations based on a consumer's personal genetic assessment. The company's mission is to empower individuals to take personal responsibility and control of their health.
Every LifeMap Me™ custom nutritional formula and LifeMap Me™ custom skin care formula is "made exclusively" for each customer. This is a revolutionary new scientific approach to delivering products that truly address individual needs. GeneWize is committed to innovating and manufacturing the highest quality, scientifically proven health, beauty and wellness products. For more information on GeneWize, please visit: www.genewize.com
This release contains certain forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in the press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement. GNLK disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future developments or otherwise.
|
